A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis

Trial Profile

A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs RNS 60 (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Revalesio
  • Most Recent Events

    • 05 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 30 Jan 2014 Planned End Date changed from 1 Feb 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.
    • 05 Sep 2013 Planned End Date changed from 1 Sep 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top